NASDAQ:EVOK Evoke Pharma (EVOK) Stock Price, News & Analysis $0.54 0.00 (0.00%) (As of 07/5/2024 ET) Add Compare Share Share Today's Range$0.54▼$0.5750-Day Range$0.43▼$0.6152-Week Range$0.40▼$1.77Volume12,189 shsAverage Volume29,599 shsMarket Capitalization$4.64 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends Get Evoke Pharma alerts: Email Address Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About Evoke Pharma Stock (NASDAQ:EVOK)Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Read More EVOK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EVOK Stock News HeadlinesJune 29, 2024 | americanbankingnews.comEvoke Pharma (NASDAQ:EVOK) Share Price Passes Below 200 Day Moving Average of $0.66June 29, 2024 | americanbankingnews.comEvoke Pharma (NASDAQ:EVOK) Receives New Coverage from Analysts at StockNews.comJuly 6, 2024 | Stansberry Research (Ad)Obama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In fact, according to Tucker Carlson, in private even "Obama is telling people Biden can't win, and he is therefore in favor of an open convention."June 17, 2024 | globenewswire.comEvoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTIMay 16, 2024 | globenewswire.comEvoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) ConferenceMay 15, 2024 | finanznachrichten.deEvoke Pharma, Inc.: Evoke Pharma Reports First Quarter 2024 Financial ResultsMay 14, 2024 | msn.comEVOK Stock Earnings: Evoke Pharma Beats EPS, Misses Revenue for Q1 2024May 14, 2024 | globenewswire.comEvoke Pharma Reports First Quarter 2024 Financial ResultsJuly 6, 2024 | Stansberry Research (Ad)Obama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In fact, according to Tucker Carlson, in private even "Obama is telling people Biden can't win, and he is therefore in favor of an open convention."May 11, 2024 | msn.comOprah apologises for being 'major contributor' to diet culture after weight loss drugs admissionApril 26, 2024 | finance.yahoo.comEvoke Pharma, Inc. (EVOK)April 17, 2024 | finance.yahoo.comEvoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 MedicationsApril 17, 2024 | globenewswire.comEvoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 MedicationsApril 10, 2024 | finanznachrichten.deDelveInsight Business Research, LLP: Gastroparesis Market to Witness Upsurge in Growth at a CAGR of 7% by 2034 | DelveInsightApril 10, 2024 | msn.comEmpowering students: Innovative approaches to climate change educationApril 10, 2024 | finance.yahoo.comStephanie Carman Joins Underscore Marketing as SVP Client Services; Tiffany Marg Joins Strategy TeamApril 1, 2024 | msn.comHow a Dubai man built a $200,000 art collection in his Business Bay homeMarch 30, 2024 | msn.comThe Secret Behind Your Soda: The Cocaine-Free Journey of Coca Leaves in Coca-ColaSee More Headlines Receive EVOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/06/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:EVOK CUSIPN/A CIK1403708 Webwww.evokepharma.com Phone(858) 345-1494FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,790,000.00 Net Margins-116.75% Pretax Margin-116.75% Return on Equity-4,908.09% Return on Assets-78.43% Debt Debt-to-Equity RatioN/A Current Ratio1.39 Quick Ratio1.32 Sales & Book Value Annual Sales$5.18 million Price / Sales0.90 Cash FlowN/A Price / Cash FlowN/A Book Value($0.77) per share Price / Book-0.70Miscellaneous Outstanding Shares8,600,000Free Float8,073,000Market Cap$4.64 million OptionableNot Optionable Beta0.38 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Matthew J. D'Onofrio MBA (Age 54)Co-Founder, CEO & Director Comp: $779.37kDr. Marilyn R. Carlson D.M.D. (Age 76)M.D., RAC., Chief Medical Officer Comp: $681.24kMr. Christopher QuesenberryChief Commercial Officer - Gimoti (TM)Key CompetitorsViracta TherapeuticsNASDAQ:VIRXLumos PharmaNASDAQ:LUMOJaguar HealthNASDAQ:JAGXTherapeuticsMDNASDAQ:TXMDSynlogicNASDAQ:SYBXView All Competitors EVOK Stock Analysis - Frequently Asked Questions How have EVOK shares performed this year? Evoke Pharma's stock was trading at $1.0503 at the beginning of the year. Since then, EVOK stock has decreased by 48.6% and is now trading at $0.54. View the best growth stocks for 2024 here. How were Evoke Pharma's earnings last quarter? Evoke Pharma, Inc. (NASDAQ:EVOK) released its earnings results on Tuesday, May, 14th. The specialty pharmaceutical company reported ($0.17) EPS for the quarter. The specialty pharmaceutical company earned $1.74 million during the quarter. Evoke Pharma had a negative trailing twelve-month return on equity of 4,908.09% and a negative net margin of 116.75%. When did Evoke Pharma's stock split? Shares of Evoke Pharma reverse split on Monday, May 23rd 2022. The 1-12 reverse split was announced on Monday, May 23rd 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Evoke Pharma? Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Evoke Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evoke Pharma investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Advanced Micro Devices (AMD), Novavax (NVAX), Sorrento Therapeutics (SRNE) and Inovio Pharmaceuticals (INO). This page (NASDAQ:EVOK) was last updated on 7/6/2024 by MarketBeat.com Staff From Our PartnersWhy Conservative Americans Are Turning to Gold in 2024Welcome to the financial rollercoaster of 2024, where inflation is relentless, stock markets are inflated, and...All American Assets | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredBill Gates is all about this tiny $2 stockWhat does Bill Gates know about this tiny company that we don’t? From the outside, it looks like a worthles...Timothy Sykes | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evoke Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evoke Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.